Cantargia AB (publ) (FRA:7V3)

Market Cap	35.10M -35.5%
Revenue (ttm)	28.66M
Net Income	15.12M
EPS	0.06
Shares Out	n/a
PE Ratio	1.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,000
Open	0.0927
Previous Close	0.0918
Day's Range	0.0927 - 0.0927
52-Week Range	0.0846 - 0.5610
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 25, 2026

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It al...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7V3

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error